微信小陈
微信小章| 产品名称： | C1R-sB7 |
|---|---|
| 商品货号： | TS212547 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | mixed; semi-attached |
| Biosafety Level： | 2 Cells contain Herpesvirus
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7. C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution.xa0 C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. |
| Genes Expressed： | Secretes HLA B7 but does not express surface HLA B7 |
| Cellular Products： | Secretes HLA B7 but does not express surface HLA B7 |
| Comments： | C1R-sB7 secretes HLA B7 but does not express surface HLA B7.
C1R-sB7 has been a reference standard in International Workshops on soluble HLA. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Iscoves Modified Dulbeccos Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by transferring floating cells to additional flasks. Attached cells may be subcultured by scraping. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 6,10 D13S317: 11,13 D16S539: 9,13 D5S818: 10,13 D7S820: 7,12 THO1: 8 TPOX: 8 vWA: 17 |
| Name of Depositor： | F Grumet |
| Year of Origin： | 1988 |
| References： | Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569 Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967 Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968 Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956 |